Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients With Concurrent Driver Gene Mutations
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Listed as NCT04552613, this NA trial focuses on EGFR Gene Mutation and NSCLC and remains completed. Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Feb 2024 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Oct 2023 — Feb 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2023 [monthly]
Recruiting NA
▶ Show 1 earlier version
-
Oct 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .